Patents by Assignee Rigel Pharmaceuticals, Incorporated
  • Patent number: 7723018
    Abstract: The present invention relates to regulation of the cell cycle. More particularly, the present invention is directed to nucleic acids encoding components of the ubiquitin ligation pathway, e.g., ubiquitin and ubiquitin-like molecules, E1, E2, and E3 proteins and their substrates, which are involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of the ubiquitin ligation pathway; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: May 25, 2010
    Assignee: Rigel Pharmaceuticals, Incorporated
    Inventors: Robert Booher, Esteban Masuda, Valeria Ossovskaya, Brian Wong
  • Patent number: 7413870
    Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: August 19, 2008
    Assignee: Rigel Pharmaceuticals, Incorporated
    Inventors: Yasumichi Hitoshi, Susan Demo, Yonchu Jenkins
  • Publication number: 20080108098
    Abstract: The present invention provides compositions and methods for modulating cell proliferation, survival, morphology, and migration. Nucleic acids encoding proteins, and proteins so encoded which are capable of modulating proliferation, survival, morphology, and migration in mammalian cells are provided. Compositions and methods for the treatment of disorders related to cell proliferation, survival, morphology and migration are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions are methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating proliferation, survival, morphology, and migration in mammalian cells.
    Type: Application
    Filed: October 4, 2007
    Publication date: May 8, 2008
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: Cindy Leo, Ying Luo, Xiang Xu, Simon Yu
  • Patent number: 7368257
    Abstract: The present invention provides compositions and methods for modulating lymphocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating lymphocyte activation are provided. Compositions and methods for the treatment of disorders related to lymphocyte dysfunction or dysregulation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating lymphocyte activation.
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: May 6, 2008
    Assignee: Rigel Pharmaceuticals, Incorporated
    Inventors: Alan C. Fu, Jun Wu, X. Charlene Liao, Helena Mancebo
  • Patent number: 7358040
    Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding MRE11, which is a protein involved in modulation of cellular proliferation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate cellular proliferation via modulation of MRE11; as well as to the use of expression profiles and compositions in diagnosis and therapy related to modulation of cellular proliferation.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: April 15, 2008
    Assignee: Rigel Pharmaceuticals, Incorporated
    Inventors: Yasumichi Hitoshi, Susan Demo, Yonchu Jenkins
  • Patent number: 7193052
    Abstract: The present invention relates to directed protein evolution in mammalian cells and improved mutants of Discosoma sp. red fluorescent proteins.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: March 20, 2007
    Assignees: Rigel Pharmaceuticals, Incorporated, Becton, Dickinson and Company
    Inventor: Beau Peelle
  • Publication number: 20060105409
    Abstract: The invention relates to assays for measuring ubiquitin ligase activity and for identifying modulators of ubiquitin ligase enzymes.
    Type: Application
    Filed: January 9, 2006
    Publication date: May 18, 2006
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: Sarkiz Issakani, Jianing Huang, Julie Sheung, Todd Pray
  • Patent number: 7005254
    Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding LETM1 (“leucine zipper EF hand transmembrane receptor”), which is involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, siRNA, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of LETM1 and LETM1 related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: February 28, 2006
    Assignee: Rigel Pharmaceuticals, Incorporated
    Inventors: Susan Demo, Yasumichi Hitoshi, Denise Pearsall
  • Publication number: 20050250163
    Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Application
    Filed: February 16, 2005
    Publication date: November 10, 2005
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James Lorens, Sacha Holland, Weiduan Xu
  • Publication number: 20050208472
    Abstract: The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Application
    Filed: January 13, 2005
    Publication date: September 22, 2005
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: Weiduan Xu, Sacha Holland, James Lorens
  • Patent number: 6927031
    Abstract: The present invention relates to methods of screening for target polypeptides that bind to RNA, using affinity purification methods, and the use of such target polypeptide for drug discovery and in methods of treating and preventing disease, e.g., HCV infection.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: August 9, 2005
    Assignee: Rigel Pharmaceuticals, Incorporated
    Inventors: Henry Lu, Weiqun Li, David Anderson
  • Publication number: 20050118604
    Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Application
    Filed: October 29, 2003
    Publication date: June 2, 2005
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James Lorens, Robert Atchison, Annabelle Friera, Sacha Holland
  • Publication number: 20040126850
    Abstract: The present invention relates to directed protein evolution in mammalian cells and improved mutants of Discosoma sp. red fluorescent proteins.
    Type: Application
    Filed: December 17, 2003
    Publication date: July 1, 2004
    Applicants: Rigel Pharmaceuticals, Incorporated, Becton, Dickinson and Company
    Inventor: Beau Peelle
  • Publication number: 20040126784
    Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding protein kinase C &zgr; (PKC-&zgr;), phospholipase C-&bgr;1 (PLC-&bgr;1), protein tyrosine kinase 2 (FAK), protein tyrosine kinase 2b (FAK2), casein kinase 2 (CK2), cMET tyrosine kinase (cMET), flap structure specific endonuclease 1 (FEN1), REV1 dCMP transferase (REV1), apurinic/apyrimidinic nuclease 1 (APE1), cyclin dependent kinase 3 (CDK3), PIM1 kinase (PIM1), cell division cycle 7 kinase (CDC7L1), cyclin dependent kinase 7 (CDK7), cytokine inducible kinase (CNK), potentially prenylated protein tyrosine phosphatase (PRL-3), serine threonine kinase 2 (STK2) or (NEK4), cyclin dependent serine threonine kinase (NKIAMRE), or histone acetylase (HBO1), which are involved in modulation of cell cycle arrest.
    Type: Application
    Filed: July 14, 2003
    Publication date: July 1, 2004
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: Yasumichi Hitoshi, Yonchu Jenkins, Vadim Markovtsov
  • Publication number: 20040116347
    Abstract: The present invention relates to regulation of inflammation. More particularly, the present invention is directed to nucleic acids encoding components of the ubiquitin ligation pathway, e.g., ubiquitin and ubiquitin-like molecules, E1, E2, and E3 proteins and their substrates, which are involved in modulation of the inflammatory process. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate the inflammatory process via modulation of the ubiquitin ligation pathway; as well as to the use of expression profiles and compositions in diagnosis and therapy related to regulation of inflammation and modulation of cytokine signaling involved in inflammation, e.g., for treatment of infection, autoimmune disease and other diseases related to the inflammatory process.
    Type: Application
    Filed: August 28, 2003
    Publication date: June 17, 2004
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: Esteban Masuda, Brian Wong
  • Patent number: 6723537
    Abstract: The present invention relates to directed protein evolution in mammalian cells and improved mutants of Discosoma sp. red fluorescent proteins.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: April 20, 2004
    Assignees: Rigel Pharmaceuticals, Incorporated, Becton, Dickinson and Company
    Inventor: Beau Peelle
  • Publication number: 20040053233
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Application
    Filed: August 30, 2002
    Publication date: March 18, 2004
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James B. Lorens, Weiduan Xu, Jakob Bogenberger, Sacha Holland
  • Publication number: 20030176333
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding contactin associated protein 3 (CASPR3), which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of CASPR3; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Application
    Filed: March 18, 2002
    Publication date: September 18, 2003
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James B. Lorens, Weiduan Xu, Jakob Bogenberger
  • Publication number: 20030109440
    Abstract: The present invention relates to regulation of T lymphocyte activation. More particularly, the present invention is directed to nucleic acids encoding GRB7, which is involved in modulation of T lymphocyte activation and TCR signaling. The invention further relates to methods for identifying and using agents, including small organic molecules, peptides, circular peptides, antibodies, lipids, antisense nucleic acids, RNAi, and ribozymes, that modulate lymphocyte activation and TCR signaling via modulation of GRB7; as well as to the use of expression profiles and compositions in diagnosis and therapy related to lymphocyte activation and suppression.
    Type: Application
    Filed: August 30, 2002
    Publication date: June 12, 2003
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: Peter Chu, Congfen Li, X. Charlene Liao, Esteban Masuda, Jorge Pardo, Haoran Zhao
  • Publication number: 20030077730
    Abstract: The present invention relates to directed protein evolution in mammalian cells and improved mutants of Discosoma sp. red fluorescent proteins.
    Type: Application
    Filed: May 20, 2002
    Publication date: April 24, 2003
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventor: Beau Peelle